Efpeglenatide

Generic Name: Efpeglenatide

Drug Type: Biotech

CAS Number: 1296200-77-5

Unique Ingredient Identifier: 3M1V5Z2270

Background: Efpeglenatide is under investigation in clinical trial NCT03713684 (Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)).

Clinical Trials

A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus

Phase 3

Recruiting

Conditions: Obesity

Interventions: Drug: Placebo
Drug: HM11260C

First Posted Date: 2023-12-18

Last Posted Date: 2024-11-05

Lead Sponsor: Hanmi Pharmaceutical Company Limited

Target Recruit Count: 420

Registration Number: NCT06174779

Locations: 🇰🇷
Kangbuk samsung hospital, Seoul, Korea, Republic of

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea

Phase 3

Terminated

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Efpeglenatide SAR439977
Drug: Placebo

First Posted Date: 2018-12-10

Last Posted Date: 2021-12-02

Lead Sponsor: Sanofi

Target Recruit Count: 312

Registration Number: NCT03770728

Locations: 🇺🇸
Investigational Site Number 8400035, Chandler, Arizona, United States
🇺🇸
Investigational Site Number 8400005, Glendale, Arizona, United States
🇺🇸
Investigational Site Number 8400056, Tucson, Arizona, United States

and more 45 locations

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

Phase 3

Terminated

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Efpeglenatide SAR439977
Drug: Placebo
Drug: Background therapy

First Posted Date: 2018-10-22

Last Posted Date: 2021-12-02

Lead Sponsor: Sanofi

Target Recruit Count: 370

Registration Number: NCT03713684

Locations: 🇺🇸
Investigational Site Number 8400005, Glendale, Arizona, United States
🇰🇷
Investigational Site Number 4100009, Busan, Korea, Republic of
🇰🇷
Investigational Site Number 4100014, Jeonju, Korea, Republic of

and more 44 locations

Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

Phase 3

Terminated

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Efpeglenatide
Drug: Dulaglutide
Drug: Background therapy Metformin

First Posted Date: 2018-09-26

Last Posted Date: 2021-11-01

Lead Sponsor: Sanofi

Target Recruit Count: 908

Registration Number: NCT03684642

Locations: 🇺🇸
Investigational Site Number 8400009, Los Angeles, California, United States
🇺🇸
Investigational Site Number 8400059, Skokie, Illinois, United States
🇺🇸
Investigational Site Number 8400061, Boston, Massachusetts, United States

and more 42 locations

Effect of Efpeglenatide on Cardiovascular Outcomes

Phase 3

Terminated

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Efpeglenatide (SAR439977)

First Posted Date: 2018-04-12

Last Posted Date: 2021-10-15

Lead Sponsor: Sanofi

Target Recruit Count: 4076

Registration Number: NCT03496298

Locations: 🇺🇸
Investigational Site Number 8400096, Philadelphia, Pennsylvania, United States
🇺🇸
Investigational Site Number 8400021, Pittsburgh, Pennsylvania, United States
🇮🇳
Investigational Site Number 3560005, Pune, India

and more 350 locations

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: efpeglenatide (SAR439977)
Drug: placebo

First Posted Date: 2017-11-27

Last Posted Date: 2022-01-18

Lead Sponsor: Hanmi Pharmaceutical Company Limited

Target Recruit Count: 406

Registration Number: NCT03353350

Locations: 🇵🇱
Investigational Site Number 6160001, Wroclaw, Poland
🇺🇸
Investigational Site Number 8400004, Birmingham, Alabama, United States
🇺🇸
Investigational Site Number 8400021, Las Vegas, Nevada, United States

and more 51 locations

Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

Phase 2

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Placebo
Drug: HM11260C

First Posted Date: 2014-03-07

Last Posted Date: 2016-08-09

Lead Sponsor: Hanmi Pharmaceutical Company Limited

Target Recruit Count: 209

Registration Number: NCT02081118

Locations: 🇺🇸
Hanmi pharmaceutical, Miami, Florida, United States

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

Phase 1

Conditions: Diabetes Mellitus

Interventions: Drug: HM11260C
Drug: Victoza
Drug: Placebo

First Posted Date: 2014-02-11

Last Posted Date: 2014-02-11

Lead Sponsor: Hanmi Pharmaceutical Company Limited

Target Recruit Count: 44

Registration Number: NCT02059564

Locations: 🇺🇸
Hanmi, California, California, United States

Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

Phase 2

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: HM11260C
Drug: Placebo
Drug: liraglutide

First Posted Date: 2014-02-06

Last Posted Date: 2016-08-09

Lead Sponsor: Hanmi Pharmaceutical Company Limited

Target Recruit Count: 254

Registration Number: NCT02057172

Locations: 🇺🇸
Hanmi pharmaceutical, CA, California, United States

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: HM11260C
Drug: Placebo

First Posted Date: 2011-10-14

Last Posted Date: 2016-08-09

Lead Sponsor: Hanmi Pharmaceutical Company Limited

Target Recruit Count: 72

Registration Number: NCT01452451

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy